Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : African Union drops AstraZeneca vaccine, which COVAX will supply

04/08/2021 | 01:13pm EDT
FILE PHOTO: Vials and medical syringe are seen in front of J&J logo in this illustration

NAIROBI (Reuters) - The African Union's disease control body said on Thursday it had dropped plans to secure AstraZeneca COVID-19 vaccines for its members from the Serum Institute of India, the world's biggest vaccine supplier, amid global shortfalls of the shot.

AstraZeneca's $3 shot is by far the cheapest coronavirus vaccine launched so far, and the easiest to store and transport, making it well suited to developing countries.

On Wednesday, European and British medicine regulators said they had found possible links between the vaccine and extremely rare cases of brain blood clots, while emphatically reaffirming its importance in mass vaccination against COVID-19.

John Nkengasong, head of the Africa Centres for Disease Control and Prevention (Africa CDC), said the AU's decision had nothing to do with those findings, and reiterated his advice that the benefits of the vaccine outweighed the risks.

He said the main reason was to avoid duplicating COVAX's efforts by the World Health Organization-backed COVAX facility, which will continue to supply AstraZeneca to Africa.

He said the AU was focusing on the Johnson & Johnson vaccine, citing a deal announced last week to supply Africa with up to 400 million doses.

COVAX aims to deliver 600 million shots - most of them from AstraZeneca - to some 40 African countries this year, enough to vaccinate 20% of their populations.

Africa trails most other regions in COVID-19 vaccinations; fewer than 13 million doses have been administered on a continent of 1.3 billion people, according to the Africa CDC.


The AU had wanted to secure up to 500 million additional AstraZeneca shots for its 55 member states, at $3 per shot.

However, last month India suspended its exports to meet rising domestic demand.

Nkengasong said the subsequent delays were complicating vaccination across Africa, noting that health systems had to know that second doses would be available in time for those who had received a first dose.

Matshidiso Moeti, who heads the WHO's Africa office, confirmed the two organisations wanted to ensure they were "not competing and stepping over each other looking for the same vaccines".

"I am very much assured that it is not to do with doubts about the safety and other considerations on the AstraZeneca vaccines. It's simply to recognise that there are challenges with the volumes that are available," she told a separate news briefing.

The single-shot J&J doses secured last week will not arrive until the third quarter, and Nkengasong said Africa would find it hard to bridge the gap in the meantime.

South Africa has cancelled orders of the AstraZeneca vaccine after finding it gave only minimal protection against mild-to-moderate infection caused by the country's dominant, highly infectious variant.

Russia and China are also offering vaccines, but there are questions about their cost and availability in large volumes.

The virus is confirmed to have killed 114,000 people across Africa, and infected 4.33 million.

(Reporting by Maggie Fick; Writing by Katharine Houreld; Editing by Alex Richardson, Nick Macfie and Alison Williams)

© Reuters 2021
All news about ASTRAZENECA PLC
06:47aEU to Focus on mRNA-based COVID-19 Jabs, Likely to Ditch AstraZeneca, Johnson..
05:18aASTRAZENECA  : CEO Says Borders Need To Open To Keep Sharing Vaccines Through CO..
05:03aASTRAZENECA  : Indian vaccine maker Serum Institute appeals to Biden to lift emb..
04:06aASTRAZENECA  : vaccine available to walk-ins
02:29aASTRAZENECA  : India extends record rise in COVID-19 cases, election rallies con..
04/15MARKET CHATTER : Elliott Management Secures 'Significant' Shareholding in GlaxoS..
04/15ANALYSIS : India shifts from mass vaccine exporter to importer, worrying the wor..
04/15MODERNA  : Fauci says he believes J&J vaccine will 'get back on track soon'
04/15ASTRAZENECA  : Quebec officials satisfied with AstraZeneca rollout despite empty..
04/15JOHNSON & JOHNSON  : Poland's vaccines chief not ruffled by church objections
More news
Financials (USD)
Sales 2021 30 821 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 685 M - -
P/E ratio 2021 26,1x
Yield 2021 2,80%
Capitalization 134 B 134 B -
EV / Sales 2021 4,72x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 101,99 $
Spread / Highest target 62,7%
Spread / Average Target 27,1%
Spread / Lowest Target -7,66%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.91%422 260
ROCHE HOLDING AG-0.02%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-4.51%197 072
MERCK & CO., INC.-6.28%194 049